

News Release

October 17, 2025

Human Life CORD Raises 1.57 Billion Yen in Series C Second Close

– Advancing Preparation for Phase III Clinical Trial and Accelerating Global Expansion –

Human Life CORD Japan Inc. (Head Office: Chuo-ku, Tokyo; President & CEO: Masamitsu Harata; hereinafter “HLC”), a company pioneering the practical application and global deployment of umbilical cord-derived mesenchymal stromal cells (UC-MSCs) as regenerative medicine products, has raised a total of 1.57 billion yen in its Series C Second Close.

This additional financing was completed through FUNDINNO PLUS+, a qualified-investor platform operated by FUNDINNO Inc., Japan’s leading equity crowdfunding company.

The fundraising reflects strong investor confidence in HLC’s UC-MSC-based global ecosystem business model and its advancing clinical development programs.

With the newly raised capital, HLC will reinforce its development framework for the company’s lead pipeline program — a Phase III clinical trial for Noninfectious pulmonary complications (NIPCs) following hematopoietic stem-cell transplantation — and accelerate the establishment of a global UC-MSC manufacturing and supply network to realize the earliest possible commercialization of UC-MSC-based regenerative therapies.

Masamitsu Harata, President and CEO of Human Life CORD Japan Inc., commented:

“Guided by our vision of realizing a co-creative society, we have advanced hand-in-hand with many partners who share our mission.

I sincerely appreciate the trust of the new angel investors who have joined us in this journey.

The patient-money entrusted to us through this financing is a profound symbol of confidence — and also a reminder of our responsibility.

We will continue striving to deliver a sustainable, umbilical-cord-derived cell therapy to society, bringing hope to patients suffering from rare and intractable diseases such as post-transplant idiopathic pneumonia syndrome.

Our mission is to connect as many lives as possible to the future, as swiftly as possible.”



About FUNDINNO PLUS+

FUNDINNO PLUS+ is a service operated by FUNDINNO Inc., which also runs Japan's first equity-based crowdfunding platform "FUNDINNO."

It enables qualified investors registered with FUNDINNO to invest directly in promising unlisted companies.

For more information, please visit;

https://fundinno.com/plus/plus_projects/view_h6u8mznx

About Human Life CORD, Inc.

(<https://humanlifecord.com>)

Human Life CORD, Inc. develops and manufactures umbilical cord-derived cell products that can be domestically sourced and cryopreserved in Japan. Our mission is to transform umbilical cords—often discarded after birth—into sources of life-saving cell therapies for patients with unmet medical needs, and eventually into preventive medicine that extends healthy life expectancy. Awards include: Tokyo Venture Championship Grand Prize & Governor of Tokyo Award (2019), Japan Open Innovation Award – Minister of Health, Labour and Welfare Award (2023), J-Startup selected company (2023), and the Tokyo Chamber of Commerce and Industry "Courageous Management Award" – Startup Division Grand Prize (2024).

[Contact for Media Inquiries]

Public Relations, Human Life CORD Japan Inc.

Attn: Yuki Hayashi

TEL: +81-80-4671-0405

Email: info@humanlifecord.com